Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health Prices $500 Million Convertible Senior Notes Offering
Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
Guardant360® Tissue Receives MOHW LDTS approval in Taiwan
PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
Guardant Health, Inc. 2026 Q3 - Results - Earnings Call Presentation
Piper Sandler Maintains Overweight on Guardant Health, Lowers Price Target to $190
Guardant Health to Participate in Upcoming Investor Conferences
GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability
This cancer-testing stock is BTIG’s top pick after another major earnings beat
Guardant Health (GH) Now Has A Harder Patent Fight After 23 Claims Survived
Guardant Health Stocks Fall 9.49% as Cash Burn Outlook Rises Despite 36% Growth
Guardant Health, Inc. Q3 2026 Earnings Call Summary
Guardant Health Shares Fall 5.5% as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth
Guardant Health (GH) Q3 2026 Earnings Call Transcript
Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36% as Shield ...
What Guardant Health (GH) Said on Its Q3 Earnings Call
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
Guardant Health Inc (NASDAQ:GH) Falls 12% Despite In-Line Q3 Revenue as Guidance Disappoints
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.